tradingkey.logo

Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue

ReutersApr 30, 2025 11:26 AM

- Surmodics Inc SRDX.O:

  • SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE

  • SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS

  • SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES

  • SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI